Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle
Phase of Trial: Phase III
Latest Information Update: 16 Nov 2017
At a glance
- Drugs Ingenol disoxate (Primary)
- Indications Actinic keratosis
- Focus Therapeutic Use
- Sponsors LEO Pharma
- 20 Jul 2017 Status changed from not yet recruiting to recruiting.
- 02 Jun 2017 Planned End Date changed from 31 Oct 2019 to 30 Nov 2019.
- 02 Jun 2017 Planned primary completion date changed from 31 Oct 2019 to 30 Nov 2019.